BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

Current status and clinical application of patient-derived tumor organoid model using in kidney and prostate cancers
Minyong Kang 2,3,4,* (Professor), Eunjeong Seo 1 (Research worker)
1Molecular pharmacology, OliPass Corporation, Yongin, Gyeonggi, Republic of Korea,
2Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine,
3Department of Health Sciences and Technology, SAIHST,
4Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea
Urological cancers such as kidney, bladder, prostate, and testicular cancers are the most common types of cancers worldwide with high mortality and morbidity. To date, traditional cell lines and animal models have been broadly used to study pre-clinical applications and underlying molecular mechanisms of urological cancers. However, they cannot reflect biological phenotypes of real tissues and clinical diversities of urological cancers in vitro system. In vitro models cannot be utilized to reflect the tumor microenvironment or heterogeneity. Cancer organoids in three-dimensional culture have emerged as a promising platform for simulating tumor microenvironment and revealing heterogeneity. In this review, we summarize recent advances in prostate and kidney cancer organoids regarding culture conditions, advantages, and applications of these cancer organoids.
Abstract, Accepted Manuscript(in press) [Submitted on November 28, 2022, Accepted on December 2, 2022]
  © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd